CN115297882A - 用于治疗呼吸道感染的组合物及其用途 - Google Patents

用于治疗呼吸道感染的组合物及其用途 Download PDF

Info

Publication number
CN115297882A
CN115297882A CN202180021765.1A CN202180021765A CN115297882A CN 115297882 A CN115297882 A CN 115297882A CN 202180021765 A CN202180021765 A CN 202180021765A CN 115297882 A CN115297882 A CN 115297882A
Authority
CN
China
Prior art keywords
seq
peptide
group
subject
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180021765.1A
Other languages
English (en)
Chinese (zh)
Inventor
安德鲁·吉尔林
D·肯利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Horizontal Intellectual Property Private Ltd
Original Assignee
Horizontal Intellectual Property Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900807A external-priority patent/AU2020900807A0/en
Application filed by Horizontal Intellectual Property Private Ltd filed Critical Horizontal Intellectual Property Private Ltd
Publication of CN115297882A publication Critical patent/CN115297882A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57554—Prolactin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CN202180021765.1A 2020-03-16 2021-03-16 用于治疗呼吸道感染的组合物及其用途 Pending CN115297882A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2020900807 2020-03-16
AU2020900807A AU2020900807A0 (en) 2020-03-16 Compositions for treating respiratory tract infection and uses thereof
AU2020900818 2020-03-17
AU2020900818A AU2020900818A0 (en) 2020-03-17 Compositions for treating respiratory tract infection and uses thereof
AU2020904226 2020-11-16
AU2020904226A AU2020904226A0 (en) 2020-11-16 Compositions for treating respiratory tract infection and uses thereof
PCT/AU2021/050229 WO2021184062A1 (en) 2020-03-16 2021-03-16 Compositions for treating respiratory tract infection and uses thereof

Publications (1)

Publication Number Publication Date
CN115297882A true CN115297882A (zh) 2022-11-04

Family

ID=77767913

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180021765.1A Pending CN115297882A (zh) 2020-03-16 2021-03-16 用于治疗呼吸道感染的组合物及其用途

Country Status (7)

Country Link
US (1) US20230256059A1 (https=)
EP (1) EP4121084A4 (https=)
JP (1) JP2023518376A (https=)
CN (1) CN115297882A (https=)
AU (1) AU2021237981A1 (https=)
CA (1) CA3171917A1 (https=)
WO (1) WO2021184062A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021003531A1 (en) * 2019-07-09 2021-01-14 Lateral IP Pty Ltd Peptides and uses thereof
JP2024516327A (ja) * 2021-05-07 2024-04-12 ラテラル、ファーマ、プロプライエタリー、リミテッド 炎症性気道疾患を処置するための組成物及びその使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140094401A1 (en) * 2012-09-13 2014-04-03 The Mitre Corporation Mitrecin a polypeptide with antimicrobial activity
US20150079044A1 (en) * 2011-12-09 2015-03-19 Metabolic Pharmaceuticals Pty Ltd Use of growth hormone fragments
WO2019136528A1 (en) * 2018-01-15 2019-07-18 Lateral IP Pty Ltd Peptides and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20080333A0 (fi) * 2008-05-02 2008-05-02 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
KR20220124196A (ko) * 2019-12-27 2022-09-13 레터럴 아이피 피티와이 리미티드 사이클릭 펩티드 수용체 란티오닌 신테타제 c-유사 단백질 (lancl) 및 이의 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150079044A1 (en) * 2011-12-09 2015-03-19 Metabolic Pharmaceuticals Pty Ltd Use of growth hormone fragments
US20140094401A1 (en) * 2012-09-13 2014-04-03 The Mitre Corporation Mitrecin a polypeptide with antimicrobial activity
WO2019136528A1 (en) * 2018-01-15 2019-07-18 Lateral IP Pty Ltd Peptides and uses thereof
CN112218650A (zh) * 2018-01-15 2021-01-12 单侧Ip私人有限公司 肽及其用途

Also Published As

Publication number Publication date
JP2023518376A (ja) 2023-05-01
AU2021237981A1 (en) 2022-10-13
EP4121084A4 (en) 2024-04-03
WO2021184062A1 (en) 2021-09-23
CA3171917A1 (en) 2021-09-23
US20230256059A1 (en) 2023-08-17
EP4121084A1 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
US9884032B2 (en) Esters of short chains fatty acids for use in the treatment of immunogenic disorders
CN115297882A (zh) 用于治疗呼吸道感染的组合物及其用途
CA2817787C (en) Composition comprising a peptide and an inhibitor of viral neuraminidase
CN114206368A (zh) 肽及其用途
WO2023165566A1 (zh) 治疗、预防由病毒感染引起的相关疾病的药物及其用途
ES2982915T3 (es) Interferones híbridos para tratar infecciones virales
CN111803635B (zh) 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用
KR20240036634A (ko) 란티오닌 합성효소 c-유사 단백질(lancl)에 결합할 수 있는 펩티드 조성물 및 그의 용도
EP4346867A1 (en) Compositions for treating inflammatory airway disease and uses thereof
JP5232520B2 (ja) ロキソプロフェンを含有する抗アデノウイルス剤
KR20070012522A (ko) 면역조절제 화합물로의 호흡기 바이러스 감염의 치료 및예방
US12492223B2 (en) Peptide compositions capable of binding lanthionine synthetase C-like protein (LanCl) and uses thereof
RS51494B (sr) Upotreba agomelatina za dobijanje lekova namenjenih lečenju periventrikularne leukomalacije
AU2006201655A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders
RU2498797C2 (ru) Комбинированное средство для лечения гриппа и орви
WO2006095433A1 (ja) ウシの消化器疾患治療剤
HK40082469A (en) Hybrid interferons for treating viral infections
HK40082469B (en) Hybrid interferons for treating viral infections
CN111655251A (zh) 用于治疗鼻病毒的羟基苯甲酸的酯
HK1210058B (en) Pharmaceutical composition comprising propionic acid for use in the treatment of viral infections
Barnard et al. Effects of the Addition of Hiltonol®(Poly-ICLC) to a SARS-CoV S Protein Vaccine in Lethal SARS-CoV Mouse Model
TW201436803A (zh) 用以提升血小板數目、降低中度以下肝纖維化指數病患之肝炎復發率以及增進社交功能之組合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination